Jennifer J. Davagian, President & CEO
Jennifer J. Davagian is the Chief Executive Officer, President and Chairperson of the Board of Managers. Ms. Davagian has 20+ years experience assembling teams of individuals to build businesses from conception to commercialization. As an IBD patient, Jennifer knows the daily struggles of patients and compliance decisions facing healthcare outcomes. As a business woman in the area of Science, Technology and Manufacturing, she has a keen understanding of new medical technology development, regulatory submissions and GMP compliance, in addition to new product commercial execution. Ms. Davagian teaches at Boston University School of Management on a variety of business topics. She has written for both the National Institute of Health and the Food and Drug Administration.
Mark C. Ensign, CSO
Mark C. Ensign is the Chief Science Officer and has over 24 years of business experience. Mr. Ensign is a multi-disciplinary scientist and holds several degrees. He oversees the research operations including the strategic direction of Cristcot’s drug pipeline, and provides this guidance to the CEO and Board of Directors. Mr. Ensign is intimately familiar with all aspects of product development within the organization and the evaluation/selection of business partners including; formulation development, laboratories, toxicological studies, clinical research organizations, API and excipient suppliers, medical and regulatory consultants, and manufacturing.
Mark A. Parent, CFO
Mark A. Parent is the Chief Financial Officer and has over 20 years of business experience. Mr. Parent is an accomplished CFO/COO with expertise in business strategy and executing successful financial initiatives. Mr. Parent is Cristcot’s part-time CFO, assisting senior management with planning and modeling future trends in business lines, and anticipating capital needs. He is an expert in accounting, financial statement reporting, tax strategies, cash management, asset/liability assessment, and company-wide integration of financial analysis. Mr. Parent previously worked at companies with revenue ranging from $6M-$41M. In his previous engagements, he oversaw both accounting and business development, leveraged company assets to accelerate sales, and identified metrics based performance for company strategic plans. He has also assisted in taking a private company public. Mr. Parent has a B.S. in accounting.
Mukul Agrawal, Regulatory Strategist
Dr. Agrawal is a Pharmaceutical Sciences consultant with over 15 years of pharmaceutical industry experience and works with clients to develop strategies for successful development and US FDA approval of various dosage forms. He has worked extensively with FDA and others to develop bioequivalence strategies for products for which no clear guidance was available he has experience preparing and submitting expert position papers for FDA review. Dr. Agarwal has also participated in several FDA meetings such as Pre-IND, NDA and ANDA meetings and has also served on the FDA’s Advisory Committee for Pharmaceutical Sciences and Clinical Pharmacology as a representative of the Generic Pharmaceutical Association. (GPhA)